IMS Health Announces $250 Million Share Repurchase Authorization
17 December 2015 - 10:30PM
Business Wire
IMS Health Holdings, Inc. (NYSE:IMS) today announced that its
board of directors approved a stock repurchase program authorizing
the repurchase of up to $250 million of its common stock.
The share repurchase program does not obligate the company to
repurchase any particular amount of common stock, and it could be
modified, suspended or discontinued at any time. The timing and
amount of repurchases are determined by IMS Health’s management at
its discretion based on a variety of factors such as the market
price of its common stock, corporate requirements, general market
and economic conditions, legal requirements and compliance with the
terms of the company’s senior secured credit facilities and the
indentures governing its outstanding senior notes. Purchases of the
company’s common stock may be made in open market transactions
effected through a broker-dealer at prevailing market prices, in
block trades, in privately negotiated transactions or by other
means in accordance with federal securities laws. The share
repurchase program does not have a specified expiration date.
About IMS Health
IMS Health is a leading global information and technology
services company providing clients in the healthcare industry with
end-to-end solutions to measure and improve their performance. Our
7,500 services experts connect configurable SaaS applications to
10+ petabytes of complex healthcare data in the IMS One™ cloud
platform, delivering unique insights into diseases, treatments,
costs and outcomes. The company’s 15,000 employees blend global
consistency and local market knowledge across 100 countries to help
clients run their operations more efficiently. Customers include
pharmaceutical, consumer health and medical device manufacturers
and distributors, providers, payers, government agencies,
policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS
Health uses anonymous healthcare data to deliver critical,
real-world disease and treatment insights. These insights help
biotech and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders to
identify unmet treatment needs and understand the effectiveness and
value of pharmaceutical products in improving overall health
outcomes. Additional information is available at
www.imshealth.com.
IMSFIN
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151217005243/en/
IMS Health Holdings, Inc.Tom Kinsley, +1.203.448.4691Investor
Relationstkinsley@imshealth.comorTor Constantino,
+1.484.567.6732Media Relationstconstantino@us.imshealth.com
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ims Health Holdings, Inc. (New York Stock Exchange): 0 recent articles
More Ims Health Holdings, Inc. News Articles